Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment

Dolutegravir (DTG) is a first-line antiretroviral drug (ARV) used in combination therapy for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. The drug is effective, safe, and well tolerated. Nonetheless, concerns have recently emerged for its usage in pregnant women or those o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bade, Aditya N., McMillan, JoEllyn M., Liu, Yutong, Edagwa, Benson J., Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599359/
https://www.ncbi.nlm.nih.gov/pubmed/34390469
http://dx.doi.org/10.1007/s12035-021-02508-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599359/
https://www.ncbi.nlm.nih.gov/pubmed/34390469
http://dx.doi.org/10.1007/s12035-021-02508-5

Ejemplares similares